Related Experiment Video

Updated: Oct 2, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Effect of very-low-dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy

Jennifer Wink1, George Giacoppe, James King

  • 1Department of Medicine, Madigan Army Medical Center, Tacoma, WA 98431, USA.

American Heart Journal
|February 28, 2002
PubMed

Insights

Very low-dose niacin, when added to statin therapy, significantly increases high-density lipoprotein cholesterol (HDLC) levels. This approach offers a safer alternative to traditional niacin doses, with minimal side effects for coronary artery disease risk reduction.

Area of Science:

  • Cardiology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Low high-density lipoprotein cholesterol (HDLC) is a significant risk factor for coronary artery disease.
  • Niacin effectively raises HDLC but is limited by dose-dependent side effects.
  • Investigating very low-dose niacin with statins aims to mitigate side effects while improving lipid profiles.

Purpose of the Study:

  • To evaluate the efficacy of very low-dose niacin in combination with statin therapy.
  • To determine if this combination significantly increases HDLC levels.
  • To assess the side effect profile compared to traditional niacin doses.

Main Methods:

  • A randomized, double-blind, placebo-controlled trial involving 50 patients on stable statin therapy.
  • Participants received either placebo or 50 mg niacin twice daily for 3 months.
  • Exclusion criteria included diabetes and active smoking; primary endpoints were changes in HDLC and reported side effects.

Main Results:

  • The addition of very low-dose niacin to statin therapy resulted in a significant mean increase in HDLC (2.1 mg/dL, p=0.0246).
  • Flushing was reported by 5 patients in the niacin group versus 2 in the placebo group.
  • No major side effects were observed, and no patients discontinued medication due to adverse events.

Conclusions:

  • Very low-dose niacin, when combined with statin therapy, effectively increases HDLC cholesterol.
  • This therapeutic strategy appears to avoid the significant side effects associated with higher niacin doses.
  • The findings support the use of very low-dose niacin as an adjunct to statins for managing lipid profiles.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...